Genetically modified T-cell therapy granted enhanced EMA regulatory pathway: KTE-C19

Kite Pharma granted access to PRIME regulatory support for KTE-C19 to treat chemorefractory DLBCL In a press release, Kite Pharma announced that it is?among first sponsors selected to participate in the EMAs enhanced regulatory program for investigational therapies that promise significant advances against serious diseases. ?The?European Medicines Agency (EMA) Committee for Medicinal Products for Human[…]

Pharmacogenomics, the answer to ?A Very Personal Problem??

Scientific American Pharmacogenomics, the answer to ?A Very Personal Problem?? Using pharmacogenomics when prescribing medications has the potential to prevent serious side effects. ?Although the technology is inexpensive, only a few US hospitals take advantage of the genetic diagnostics. St. Jude?s and Vanderbilt University Medical Center are among the hospitals that do.? According to the[…]